Merck
  • Home
  • Search Results
  • Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat.

Telmisartan reduces progressive accumulation of cellular amyloid beta and phosphorylated tau with inflammatory responses in aged spontaneously hypertensive stroke resistant rat.

Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2014-09-23)
Tomoko Kurata, Violeta Lukic, Miki Kozuki, Daisuke Wada, Kazunori Miyazaki, Nobutoshi Morimoto, Yasuyuki Ohta, Kentaro Deguchi, Yoshio Ikeda, Tatsushi Kamiya, Koji Abe
ABSTRACT

In addition to reducing the level of blood pressure (BP), telmisartan was expected to show the long-term neuroprotective effects preventing accumulation of cellular amyloid beta peptide (Aβ) and phosphorylated tau (pτ) by ameliorating neuroinflammation. We examined effects of telmisartan on cellular Aβ and pτ with inflammatory responses in the brain of a spontaneously hypertensive stroke resistant (SHR-SR) rat by giving either telmisartan at 0 (vehicle), .3 mg/kg/day or 3 mg/kg/day, orally, from 3 months of age and performed immunohistologic analysis at 6, 12, and 18 months. Compared with normotensive Wistar rats, numbers of Aβ- and pτ-positive neurons in the cerebral cortex progressively increased with age until 18 months in the SHR-SR rats, as did the numbers of ionized calcium-binding adapter molecule 1 (Iba-1)-positive microglia, tumor necrosis factor alpha (TNF-α)-positive neurons, and monocyte chemotactic protein 1 (MCP-1)-positive neurons. Low-dose telmisartan significantly decreased the numbers of Aβ- and pτ-positive neuron as well as the numbers of TNF-α-positive neurons, Iba-1-positive microglia, and MCP-1-positive neurons at 6, 12, and 18 months. High-dose telmisartan reduced BP and showed a further reduction of cellular Aβ and pτ. The present study suggests that accumulation of cellular Aβ and pτ and the inflammatory responses were decreased via improving metabolic syndrome with low-dose telmisartan and improving both metabolic syndrome and hypertension with high-dose telmisartan.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Threonine, from non-animal source, meets EP, JP, USP testing specifications, suitable for cell culture, 99.0-101.0%
Sigma-Aldrich
L-Threonine, BioXtra, ≥99.5% (NT)
SAFC
L-Threonine
Sigma-Aldrich
L-Threonine, reagent grade, ≥98% (HPLC)
Supelco
L-Threonine, certified reference material, TraceCERT®
Sigma-Aldrich
L-Threonine, Vetec, reagent grade, ≥98%
Supelco
L-Threonine, Pharmaceutical Secondary Standard; Certified Reference Material
L-Threonine, European Pharmacopoeia (EP) Reference Standard
Telmisartan for peak identification, European Pharmacopoeia (EP) Reference Standard
Telmisartan for system suitability, European Pharmacopoeia (EP) Reference Standard
Serine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
DL-Serine, BioReagent, suitable for cell culture, suitable for insect cell culture, ≥98% (HPLC)
Sigma-Aldrich
DL-Serine, ≥98% (TLC)
Sigma-Aldrich
Telmisartan, ≥98% (HPLC), solid
Telmisartan, European Pharmacopoeia (EP) Reference Standard
USP
Telmisartan, United States Pharmacopeia (USP) Reference Standard